News Medical on MSN23h
Expert explores the expanding applications of GLP1 therapiesSemaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
Hosted on MSN2mon
Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here's what the science saysThe craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better known under the trade names Ozempic and Wegovy, is remarkable ...
Hosted on MSN14d
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
HealthDay on MSN17d
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/YearExpanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...
The company announced the positive data for the dual glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide (GIP) receptor agonist at ObesityWeek 2024, taking place in Texas ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...
OBJECTIVE Gastric bypass (GB ... Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB, suggesting that its action contributes to alteration in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback